Novavax's COVID-19 & Influenza Vaccines Show Strong Phase 3 Results

"Novavax's Covid-19-influenza combination and stand-alone influenza vaccine candidates showed robust immune responses and were well tolerated in initial cohort of a phase 3 trial

Overview

Novavax, Inc. announced results of the initial cohort of its Covid-19-Influenza Combination (CIC) and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza (tNIV) phase 3 trial that showed both the CIC and flu vaccine candidates induced immune responses similar to licensed comparators Nuvaxovid and Fluzone HD, respectively. This cohort was designed to provide descriptive data on three flu strains (H1N1, H3N2, B) and SARS-CoV-2 (Covid-19) to inform a future registrational phase 3 programme.

Statement from the EVP: Novavax

• ""Both our combination and stand-alone flu vaccine candidates induced robust immune responses and were well tolerated,"" said Ruxandra Draghia-Akli, MD, PhD, executive vice president and head of research and development, Novavax. 

• ""This data set adds to findings from our phase 2 trial and will help inform discussions with potential partners.""

Potent response

• Both stand-alone flu and CIC vaccine candidates induced robust immune responses to the vaccine strains (2.4-5.7-fold over baseline). 

• Both vaccine candidates were well tolerated and saw reactogenicity comparable to authorized comparators. 

• Nearly all (>98%) solicited adverse events were mild or moderate in severity.

Day 28 Neutralizing Antibody Responses Following Administration of CIC, tNIV, Fluzone HD and Nuvaxovid Vaccines.

Aim of the trial

• This descriptive trial was designed to evaluate the safety and immunogenicity of the CIC and stand-alone flu vaccine candidates compared to Nuvaxovid and Fluzone HD in approximately 2,000 adults aged 65 and older. 

• This trial was not adequately powered to demonstrate statistical significance. 

• These results build on previous phase 2 data.

Novavax, Inc. for vaccines

Novavax, Inc. tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!